Document:

Document

Exhibit 10.1
BEIGENE, LTD.

INDEPENDENT DIRECTOR COMPENSATION POLICY

The purpose of this Independent Director Compensation Policy (this “Policy”) of BeiGene, Ltd. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who meet the general independence requirements under NASDAQ Rule 5605(a)(2) and Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. In furtherance of this purpose, all members of the Board of Directors (the “Board”) of the Company who are independent directors under NASDAQ Rule 5605(a)(2) shall be paid compensation for services provided to the Company as set forth below:

Cash Retainers

						
	Annual Retainer for Board Membership
	For general availability and participation in meetings and conference calls of the Board. No additional compensation for attending individual Board meetings.	$60,000
	Additional Annual Retainers for Committee Membership and Service as Chairperson

	Audit Committee Chairperson:	$22,500
	Audit Committee member:	$12,500
	Compensation Committee Chairperson:	$17,500
	Compensation Committee member:	$10,000
	Nominating and Corporate Governance Committee Chairperson:
	$12,500
	Nominating and Corporate Governance Committee member:
	$7,500
	Commercial and Medical Affairs Advisory Committee Chairperson:
	$16,500
	Commercial and Medical Affairs Advisory Committee member:
	$9,000
	Scientific Advisory Committee Chairperson:
	$16,500
	Scientific Advisory Committee member:
	$9,000
	No additional compensation for attending individual committee meetings.

All cash retainers will be paid quarterly, in arrears, or upon the earlier resignation or removal of the independent director. Cash retainers owing to independent directors shall be annualized, meaning that independent directors who join the Board during the calendar year, such amounts shall be pro-rated based on the number of calendar days served by such director.

Equity Retainers

Upon initial election or appointment to the Board: An initial equity grant (the “Initial Grant”) on the date of such election or appointment (the “grant date” for the Initial Grant) with an initial value of $400,000 on the grant date, pro-rated based on the number of calendar days to be served from the grant date until the first anniversary of the most recent Annual Meeting. 

Annual equity grants: On the date of the Company’s Annual Meeting of Shareholders (the “Annual Meeting”), each continuing independent member of the Board who is eligible to receive awards under this Plan will receive an annual equity grant (the “Annual Grant”) with an initial value of $400,000 on the date of grant.

Terms and Conditions of Initial Grant and Annual Grant: Each of the Initial Grant and the Annual Grant (together, the “Equity Awards”) shall consist of 50% share options (“Options”) and 50% restricted share units (“RSUs”); provided, however, that to the extent that a grant of RSUs is subject to shareholder approval pursuant to applicable listing rules, (i) the Initial Grant shall consist of 100% Options and (ii) the Annual Grant shall include RSUs only upon shareholder approval and, in the absence of such shareholder approval, the Annual Grant shall consist of 100% Options. The number of Options awarded will be the applicable grant value divided by the per share option value on the date of grant determined in accordance with the Company’s standard option valuation practices, and the number of RSUs awarded will be the applicable grant value divided by the fair market value per share of the Company’s shares on the date of grant. The Options will have an exercise price equal to the higher of (i) the fair market value per share of the Company’s shares on the date of grant, and (ii) the average fair market value per share of the Company’s shares for the five trading days immediately preceding the date of grant. The Equity Awards shall be governed by, and subject to the terms and conditions of, the Company’s 2016 Share Option and Incentive Plan (as may be amended from time to time) and standard form of grant agreements in effect on the date of grant. In addition, the Equity Awards shall vest in full (i.e., in a single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director other than as set forth below or the Board determines that the circumstances warrant continuation of vesting.  In addition, all Options shall be exercisable for three years following cessation of service, and all Equity Awards shall accelerate in full upon (i) death, (ii) disability, (iii) termination of service in connection with a change of control of the Company, or (iv) upon a change of control of the Company if the director’s service continues and the awards are not assumed by the acquiror at the time of the change of control. Subject to specific terms and conditions designed for compliance with applicable tax and other regulations, directors generally may elect to defer settlement of their RSUs until six months following the date that the director ceases to serve as a director.

Limitations on Independent Director Compensation

Cash and equity compensation payable to independent directors under this Policy shall be subject to any limits, terms and conditions set forth in any Company policy or equity incentive plan or as otherwise adopted by the Board from time to time.

Expenses

The Company shall reimburse all reasonable out-of-pocket expenses incurred by independent directors in attending Board and committee meetings.

ADOPTED: November 16, 2016
EFFECTIVE: November 16, 2016
AMENDED:  June 6, 2018, June 5, 2019, April 13, 2020 and April 5, 2021*

* Changes regarding the cash retainers will become effective on April 1, 2021. 
2EX-4.2

 Exhibit 4.2 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of February 22, 2021,
by and among Artiva Biotherapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.” 

RECITALS: 

WHEREAS, the Company and certain of the Investors (the “Prior Investors”) are parties to that certain Investors’
Rights Agreement, dated as of June 25, 2020, by and among the Company and the Prior Investors (the “Prior Agreement”); 

WHEREAS, concurrently with the execution of this Agreement, the Company and certain of the Investors are purchasing shares of the
Series B Preferred Stock (as defined below) pursuant to that certain Series B Preferred Stock Purchase Agreement (as may be amended from time to time, the “Purchase Agreement”) of even date herewith; 

WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution and delivery of this Agreement; 

WHEREAS, the parties to the Prior Agreement desire to amend and restate the Prior Agreement and accept the rights and covenants hereof
in lieu of their rights and covenants under the Prior Agreement; and 
 WHEREAS, in order to induce the Company to enter into the
Purchase Agreement and to induce certain of the Investors to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company
to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement. 

NOW, THEREFORE, in consideration of the foregoing premises and for certain other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1. Definitions. For purposes of this
Agreement: 
 1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer, director or trustee of such Person, or any investment fund, venture capital fund or
registered investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person, other than a
portfolio company of such Person. 
 1.2 “Board of Directors” means the Board of Directors of the Company. 

1.3 “Certificate of Incorporation” means the Company’s Amended and Restated Certificate of Incorporation, as
amended and/or restated from time to time. 

 1.4 “Common Stock” means shares of the Company’s Common Stock,
par value $0.0001 per share. 
 1.5 “Competitor” means a Person engaged, directly or indirectly (including through
any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the development or commercialization of products that would compete with products developed or being
developed by the Company, but shall not include (i) any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than 20% of the outstanding equity of any Competitor and does not, nor do any of
its Affiliates, have a right to designate any members of the board of directors of any Competitor, or (ii) 5AM Ventures VI, L.P. (“5AM”), venBio Global Strategic Fund III, L.P. (“venBio”) , RA Capital Healthcare
Fund, L.P. (“RA Healthcare”), Blackwell Partners LLC – Series A (“Blackwell”), RA Capital Nexus Fund, L.P. (“RA Nexus,” and, collectively, together with RA Healthcare and Blackwell, “RA
Capital”), Medivate-DAvalue Fund No.03 (“Medivate”), Venrock Healthcare Capital Partners EG, L.P. (“Venrock”), RTW Master Fund, Ltd. (“RTW Master”), RTW Innovation Master Fund, Ltd.
(“RTW Innovation”), RTW Venture Fund Limited (“RTW Venture,” and collectively, together with RTW Master and RTW Innovation, “RTW Fund”), Citadel Multi-Strategy Equities Master Fund Ltd.
(“Surveyor”), Franklin Strategic Series – Franklin Biotechnology Discovery Fund (“Franklin Strategic”), Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund (together with Franklin
Strategic, “Franklin Templeton”), Cormorant Private Equity Fund III, LP (“Cormorant Private”), Cormorant Global Healthcare Master Fund, LP (“Cormorant Global”) and CRMA SPV, L.P.
(“CRMA”, and together with Cormorant Private and Cormorant Global, the “Cormorant Funds”), SMALLCAP World Fund, Inc. (together with Capital Research Management Company, “Capital Group”) and
Wellington Investor or any of their respective Affiliates. 
 1.6 “Damages” means any loss, damage, claim or
liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or
is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the
indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.7 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in
each case, directly or indirectly), Common Stock, including options and warrants. 
 1.8 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.9 “Excluded
Registration” means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration
relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities;
or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

  
 2. 

 1.10 “FOIA Party” means a Person that, in the reasonable
determination of the Board of Directors, may be subject to, and thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552
(“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement. 

1.11 “Form S-1” means such form under the Securities Act as in effect on
the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.12 “Form
S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward
incorporation of substantial information by reference to other documents filed by the Company with the SEC. 
 1.13
“GAAP” means generally accepted accounting principles in the United States as in effect from time to time. 
 1.14
“Holder” means any holder of Registrable Securities who is a party to this Agreement. 
 1.15 “Immediate
Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, domestic partner, sibling, mother-in-law, father-in-law, son-in-law,
daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, or any life partner or other member of the same household covered under the applicable domestic relations statute, of a natural person referred to herein.

 1.16 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this
Agreement. 
 1.17 “IPO” means the Company’s first underwritten public offering of its Common Stock under the
Securities Act. 
 1.18 “Key Employee” means Fred Aslan, M.D., Thomas J. Farrell, Peter Flynn, Ph.D. and Jason B.
Litten, M.D. 
 1.19 “Major Investor” means any Investor that, individually or together with such Investor’s
Affiliates, holds at least 450,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.20 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as
well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.21 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other
entity. 
 1.22 “Preferred Director” means any director of the Company that the holders of record of one or more
series of Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation. 

  
 3. 

 1.23 “Preferred Stock” means, collectively, shares of the Series A
Preferred Stock and shares of the Series B Preferred Stock. 
 1.24 “Registrable Securities” means (i) the
Common Stock issuable or issued upon conversion of the Preferred Stock; and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under
this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement. For the avoidance of doubt,
Registrable Securities shall exclude any outstanding shares of Common Stock except those referenced in clauses (i) and (ii) above. 

1.25 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.26 “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in
Section 2.12(b) hereof. 
 1.27 “SEC” means the U.S. Securities and Exchange Commission. 

1.28 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.29 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.30 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 1.31 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer
taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel (as defined below) borne and paid by the Company as provided in
Section 2.6. 
 1.32 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par
value $0.0001 per share. 
 1.33 “Series B Preferred Stock” means shares of the Company’s Series B Preferred
Stock, par value $0.0001 per share. 
 1.34 “Voting Agreement” means that certain Amended and Restated Voting
Agreement of even date herewith among the Company, the Investors and the other parties named therein 
 1.35 “Wellington
Investor” means Wellington Biomedical Innovation Master Investors (Cayman) I L.P., or any investors or permitted transferees of Registrable Securities held by investors that are advisory or subadvisory clients of Wellington Biomedical
Innovation Master Investors (Cayman) I L.P. and/or Wellington Management Company LLP. 

  
 4. 

 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five years after the
date of this Agreement or (ii) 180 days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to the outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $10 million, then the
Company shall (x) within 10 days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within 60
days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to
be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in
each case, subject to the limitations of Sections 2.1(c) and 2.3. 
 (b) Form S-3
Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least 20% of the Registrable Securities then outstanding that the
Company file a Form S-3 registration statement with respect to the outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least
$5 million, then the Company shall (i) within 10 days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within 45 days after
the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by
any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its stockholders for such registration
statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate
reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company
unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be
tolled correspondingly, for a period of not more than 60 days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any 12 month period; and provided,
further, that the Company shall not register any securities for its own account or that of any other stockholder during such 60 days. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Section 2.1(a) (i) during the period that is 60 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, a Company-initiated registration,
provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to
Section 2.1(a); or (iii) if the Initiating Holders propose 

  
 5. 

 
to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b).
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (i) during the period that is 30 days before the Company’s good faith estimate of the date of filing of, and
ending on a date that is 90 days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become
effective; or (ii) if the Company has effected two registrations pursuant to Section 2.1(b) within the 12 month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes
of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses
therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1(d);
provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Section 2.1(c), then the Initiating Holders may withdraw their request for registration and such registration will not be counted as
“effected” for purposes of this Section 2.1(d). 
 2.2 Company Registration. If the Company proposes to register
(including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in
an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company shall, subject to the
provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by
it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration
shall be borne by the Company in accordance with Section 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request
by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and
shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3, if the managing
underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would
be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders
to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters
may round the number of shares allocated to any Holder to the nearest 100 shares. 

  
 6. 

 (b) In connection with any offering involving an underwriting of shares of the
Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon
between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable
Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success
of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among
the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation
of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable
Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be
reduced below 33% of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other
stockholder’s securities are included in such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners,
members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the
foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included
in such “selling Holder,” as defined in this sentence. 
 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall use commercially reasonable efforts to: 
 (a)
prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a
majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed;
provided, however, that such 120 day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities
included in such registration; 
 (b) prepare and file with the SEC such amendments and supplements to such registration statement,
and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the
Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

  
 7. 

 (d) register and qualify the securities covered by such registration statement under
such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file
a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the underwriter(s) of such offering; 
 (f) cause all such Registrable Securities covered by such
registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP
number for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make
available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the
selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested
by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has
been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j)
after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such
securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6 Expenses of
Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting
fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $30,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company;
provided, however, that the 

  
 8. 

 
Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the
Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless
the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have
learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information
then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this
Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this Section 2: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members,
officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter
within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby
in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to
amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they
arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in
connection with such registration. 
 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will
indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and
accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each
case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages
may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Section 2.8(b) and
2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

  
 9. 

 (c) Promptly after receipt by an indemnified party under this Section 2.8 of
notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party
under this Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any
other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may
be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a
reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially prejudices the indemnifying party’s
ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either:
(i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction
and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses,
claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with
the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified
party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or
by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required
to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to
this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the
case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on
indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control;
provided, however, that the foregoing provisions shall control as to any matter provided for or addressed thereby that is not provided for or addressed by the underwriting agreement. 

  
 10. 

 (f) Unless otherwise superseded by an underwriting agreement entered into in
connection with the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and
otherwise shall survive the termination of this Agreement or any provision(s) of this Agreement. 
 2.9 Reports Under Exchange Act.
With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a
registration on Form S-3, the Company shall: 
 (a) make and keep available adequate current
public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company
under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent
accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after 90 days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any
time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time
after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the
prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder to
include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce
the number of the Registrable Securities of the Holders that are included; provided that this limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with
Section 6.9. 
 2.11 “Market Stand-off”
Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO, and ending on the date specified by the
Company and the managing underwriter (such period not to exceed 180 days), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to
purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date
of the registration statement for the IPO, or (ii) enter into any 

  
 11. 

 
swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause
(i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. Notwithstanding the foregoing, each Holder shall have the right to adopt 10b5-1 plans during said
period so long as no sales occur prior to the expiration of said period. The foregoing provisions of this Section 2.11 shall apply only to the IPO, shall not apply to transactions (including, without limitation, any swap, hedge or similar
agreement or arrangement) or announcements, in each case, relating to securities acquired in the IPO or securities acquired in open market or other transactions from and after the IPO or that otherwise do not involve or relate to shares of Common
Stock owned by a Holder prior to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the Immediate
Family Member of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be
applicable to the Holders only if all officers, directors, and stockholders individually owning more than 1% of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are
subject to the same restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power and authority to enforce
the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11
or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders that are subject to such
agreements, based on the number of shares subject to such agreements, except that, notwithstanding the foregoing, the Company and the underwriters may, in their sole discretion, waive or terminate these restrictions with respect to up to 1% of the
shares of Common Stock subject to these restrictions. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144, in each case,
to be bound by the terms of this Agreement. 
 (b) Each certificate, instrument, or book entry representing (i) the Preferred
Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar
event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN
ACCORDANCE WITH THE TERMS OF AN INVESTORS’ RIGHTS AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

  
 12. 

 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions
of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice
to the Company of such Holder’s intention to effect such sale, pledge, or transfer, provided that no such notice shall be required if the intended sale, pledge or transfer complies with SEC Rule 144. Each such notice shall describe the manner
and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and
whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from
the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other
evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted
Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a notice, legal opinion or “no action”
letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that with respect to
transfers under the foregoing clause (y) each transferee agrees in writing to be subject to the terms of this Section 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided
shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive
legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any
registration pursuant to Sections 2.1 or 2.2 shall terminate upon the earliest to occur of: 
 (a) the closing of a Deemed
Liquidation Event, as such term is defined in the Certificate of Incorporation; 
 (b) such time after consummation of the IPO as
Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; 

(c) the fifth anniversary of the IPO. 

  
 13. 

 3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors has
not reasonably determined that such Major Investor is a Competitor of the Company: 
 (a) as soon as practicable, but in any event
within 180 days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the
end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b) as soon as practicable, but in any event within 45 days after the end of each of the first three quarters of each fiscal year of
the Company and within 90 days after the end of the fourth quarter of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity
as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all
notes thereto that may be required in accordance with GAAP); 
 (c) as soon as practicable, but in any event within 45 days after the
end of each quarter of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the
period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and
stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief
executive officer of the Company as being true, complete, and correct; 
 (d) as soon as practicable, but in any event within 30 days
of the end of each month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with GAAP (except
that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); and 

(e) as soon as practicable, but in any event 30 days before the end of each fiscal year, a budget for the next fiscal year, prepared on
a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this
Section 3.1 during the period starting with the date 60 days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to
such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to
cause such registration statement to become effective. 

  
 14. 

 3.2 Inspection. The Company shall permit each Major Investor, provided that
the Board of Directors has not reasonably determined that such Major Investor is a Competitor of the Company, at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and
discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated
pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to
the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 
 3.3
Observer Rights. With respect to each of 5AM, venBio, RA Capital, Green Cross Holdings Corporation and Venrock, as long as such Investor is entitled to designate a member of the Board of Directors pursuant to the Voting Agreement, such Investor
shall be entitled to designate an individual to attend all meetings of the Board of Directors in a nonvoting observer capacity (each, a “Board Observer”) and, in this respect, the Company shall give such representative copies of all
notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided further, that the
Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between
the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company. 

3.4 Termination of Information and Observer Rights. The covenants set forth in Sections 3.1, 3.2 and 3.3 shall terminate and be of no
further force or effect (i) immediately before the consummation of the IPO, or (ii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

3.5 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for
any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of Sections 3.1, 3.2 and 3.3 of this Agreement or notice of the Company’s intention to file a
registration statement, unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.5 by such Investor), (b) is or has been independently developed or
conceived by such Investor or its agents without use of the Company’s confidential information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality such
third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in
connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.4,
provided that the Board of Directors has not reasonably determined that such prospective purchaser is a Competitor of the Company; (iii) to any existing or prospective Affiliate, partner, (or partner of a partner), limited partner,
member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality
of such information; (iv) to the extent required in connection with any routine or periodic examination or similar process by any regulatory or self-regulatory body or authority not specifically directed at the Company or the confidential
information obtained from the Company pursuant to the terms of the Agreement, including, without limitation, quarterly or annual reports; or (v) as may otherwise be required by law, regulation, rule, court order or subpoena, provided
that, except with respect to clause (iv), such Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

  
 15. 

 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the Company
proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems
appropriate, among (i) itself, (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Major Investor (“Investor Beneficial Owners”); provided that each such Affiliate or Investor Beneficial Owner (x) is not a Competitor or
FOIA Party, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, (y) agrees to enter into this Agreement and each of the Voting Agreement and the Amended and Restated Right of First Refusal
and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each such agreement (provided that any
Competitor or FOIA Party shall not be entitled to any rights as a Major Investor under Sections 3.1, 3.2 and 4.1 hereof), and (z) agrees to purchase at least such number of New Securities as are allocable hereunder to the Major Investor holding
the fewest number of Preferred Stock and any other Derivative Securities. 
 (a) The Company shall give notice (the “Offer
Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer
such New Securities. 
 (b) By notification to the Company within 20 days after the Offer Notice is given, each Major Investor may
elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares
of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company then
outstanding (assuming full conversion and/or exercise, as applicable, of all shares of Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such 20 day period, the Company shall promptly notify each Major
Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the 10 day period commencing after the Company has
given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were
entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred
Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any
other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of 90 days of the date that the Offer
Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c). 

  
 16. 

 (c) If all New Securities referred to in the Offer Notice are not elected to be
purchased or acquired as provided in Section 4.1(b), the Company may, during the 90 day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to
any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if
such agreement is not consummated within 30 days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this
Section 4.1. 
 (d) The right of first offer in this Section 4.1 shall not be applicable to: (i) Exempted Securities
(as defined in the Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of the shares of Series B Preferred Stock pursuant to the Purchase Agreement. 

(e) Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of this Section 4.1, the
Company may elect to give notice to the Major Investors within 30 days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities. Each Major Investor shall have 20 days from the date notice is
given to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor, maintain such Major Investor’s percentage-ownership position, calculated as set forth in Section 4.1(b) before giving effect to
the issuance of such New Securities. 
 4.2 Termination. The covenants set forth in Section 4.1 shall terminate and be of no
further force or effect (i) immediately before the consummation of the IPO, or (ii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

5. Additional Covenants. 

5.1 Insurance. The Company shall obtain, within 90 days of the date hereof, from financially sound and reputable insurers Directors and
Officers liability insurance and term “key-person” insurance on Fred Aslan, M.D., in an amount and on terms and conditions satisfactory to the Board of Directors, and will use commercially reasonable
efforts to cause such insurance policies for Fred Aslan, M.D. and the Company’s existing Directors and Officers liability insurance and term “key-person” insurance on Thomas J. Farrell to be
maintained until such time as the Board of Directors determines that such insurance should be discontinued. The key-person policy shall name the Company as loss payee, and neither policy shall be cancelable by
the Company without prior approval by the Board of Directors. Notwithstanding any other provision of this Section 5.1 to the contrary, for so long as a Preferred Director is serving on the Board of Directors, the Company shall not cease to
maintain a Directors and Officers liability insurance policy in an amount of at least $3 million unless approved by each of the Preferred Directors then serving on the Board, and the Company shall annually, within 120 days after the end of each
fiscal year of the Company, deliver to the holders of Preferred Stock a certification that such a Directors and Officers liability insurance policy remains in effect. 

5.2 Employee Agreements. The Company will cause each Person now or hereafter employed by it or by any subsidiary (or engaged by the
Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement. Each Key Employee shall have entered into a one
year non-solicitation agreement, substantially in the form approved by the Board of Directors prior to the date of this Agreement. Immediately prior to the Closing (as defined in the Purchase Agreement), the
Company shall increase the allocable shares of Common Stock in the stock option pool to 5,889,537. 

  
 17. 

 5.3 Employee Stock. Unless otherwise approved by the Board of Directors, including at
least two Preferred Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute
restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four year period, with the first 25% of such shares vesting following 12 months of continued employment or service, and the remaining shares
vesting in equal monthly installments over the following 36 months, and (ii) a market stand-off provision substantially similar to that in Section 2.11. Without the prior approval by the Board of
Directors, the Company shall not amend, modify, terminate, waive or otherwise alter, in whole or in part, any stock purchase, stock restriction or option agreement with any existing employee or service provider if such amendment would cause it to be
inconsistent with this Section 5.3. In addition, unless otherwise approved by the Board of Directors, the Company shall retain (and not waive) a “right of first refusal” on employee transfers until the IPO and shall have the right to
repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 
 5.4 Matters Requiring Preferred
Director Approval. So long as the holders of Preferred Stock are entitled to elect at least two Preferred Directors, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of
Directors, which approval must include the affirmative vote of at least two of the Preferred Directors: 
 (a) make, or permit any
subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

(b) make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director
of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors; 

(c) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade
accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (d) make any investment inconsistent with
any investment policy approved by the Board of Directors; 
 (e) incur any aggregate indebtedness in excess of $250,000 that is not
already included in a budget approved by the Board of Directors, other than trade credit incurred in the ordinary course of business; 

(f) otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any
“associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, including without limitation any “management bonus” or similar plan providing payments to
employees in connection with a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, except for transactions contemplated by this Agreement and the Purchase Agreement; transactions resulting in payments to or by the
Company in an aggregate amount less than $60,000 per year; or transactions made in the ordinary course of business and pursuant to reasonable requirements of the Company’s business and upon fair and reasonable terms that are approved by a
majority of the Board of Directors; 

  
 18. 

 (g) hire, terminate, or change the compensation of the executive officers, including
approving any option grants or stock awards to executive officers; 
 (h) change the principal business of the Company, enter new
lines of business, or exit the current line of business; 
 (i) sell, assign, license, pledge, or encumber material technology or
intellectual property, other than licenses granted in the ordinary course of business; or 
 (j) enter into any corporate strategic
relationship involving the payment, contribution, or assignment by the Company or to the Company of money or assets greater than $100,000. 

5.5 Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall
meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the non-employee directors and each Board Observer for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors or other meetings or events attended on behalf of the
Company or at the Company’s request. The Preferred Directors shall constitute a majority of each of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee, upon their formation. 

5.6 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with
respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, as amended (the “Bylaws”), the Certificate of
Incorporation, or elsewhere, as the case may be. 
 5.7 Indemnification Matters. The Company hereby acknowledges that one or
more of the directors nominated to serve on the Board of Directors by the Investors (each an “Investor Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the
Investors and certain of their Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Investor Director are
primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it shall be required to advance the full amount
of expenses incurred by such Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent legally permitted and as
required by the Certificate of Incorporation or the Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights such Investor Director may have against the Investor Indemnitors, and,
(c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further
agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has sought indemnification from the Company shall affect the foregoing and the
Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against the Company. The Investor Directors and the Investor
Indemnitors are intended third party beneficiaries of this Section 5.7 and shall have the right, power and authority to enforce the provisions of this Section 5.7 as though they were a party to this Agreement. 

  
 19. 

 5.8 Right to Conduct Activities. The Company hereby agrees and acknowledges that each
of 5AM, venBio, RA Capital, Medivate, Venrock, RTW Fund, Surveyor, Franklin Templeton, the Cormorant Funds, Capital Group and Wellington Investor (together with their respective Affiliates) is a professional investment organization, and as such
reviews the business plans and related proprietary information of many enterprises, some of which may compete directly or indirectly with the Company’s business (as currently conducted or as currently propose to be conducted). The Company
hereby agrees that, to the extent permitted under applicable law, any of 5AM, venBio, RA Capital, Medivate, Venrock, RTW Fund, Surveyor, Franklin Templeton, the Cormorant Funds, Capital Group and Wellington Investor (and their respective Affiliates)
shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by any of 5AM, venBio, RA Capital, Medivate, Venrock, RTW Fund, Surveyor, Franklin Templeton, the Cormorant Funds, Capital Group or Wellington
Investor (or their respective Affiliates) in any entity competitive with the Company, or (ii) actions taken by any partner, officer, employee or other representative of 5AM, venBio, RA Capital, Medivate, Venrock, RTW Fund, Surveyor, Franklin
Templeton, the Cormorant Funds, Capital Group or Wellington Investor (or their respective Affiliates) to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or
otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s
confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

5.9 Harassment Policy. The Company shall maintain in effect (i) a Code of Conduct governing appropriate workplace behavior and
(ii) an Anti-Harassment and Discrimination Policy prohibiting discrimination and harassment at the Company. 
 5.10
Cybersecurity. The Company shall use commercially reasonable efforts to ensure that the Company’s cybersecurity solution(s) (“Cybersecurity Solutions”) (x) are
up-to-date and include industry-standard protections (e.g., antivirus, endpoint detection and response and threat hunting), (y) to the extent determined necessary by the
Company or its Board of Directors, are backed by a breach prevention warranty from the vendor certifying the effectiveness of such solutions, and (z) require the vendors to notify the Company of any security incidents posing a risk to the
Company’s information (regardless of whether information was actually compromised). The Company shall evaluate on a regular basis whether the Cybersecurity Solutions should be updated to ensure continued effectiveness and industry-standard
protections. The Company shall also educate its employees about the proper use and storage of sensitive information, including regular training as determined reasonably necessary by the Company or its Board of Directors. 

5.11 Termination of Covenants. The covenants set forth in this Section 5, except for Section 5.6 and Section 5.7, shall
terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) upon a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (a) is an Affiliate of a Holder; or (b) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members;
provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being
transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of
determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (i) that is an Affiliate or stockholder of a Holder; (ii) who is a Holder’s Immediate Family Member; or (iii)

  
 20. 

 
that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that
all transferees who would not qualify individually for assignment of rights shall, as a condition to the applicable transfer, establish a single attorney-in-fact for the
purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties.
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this
Agreement, except as expressly provided herein. 
 6.2 Governing Law. This Agreement shall be governed by the internal law of the
State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

6.3 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, the Uniform Electronic
Transactions Act or other applicable law) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. 

(a) All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail during the recipient’s normal business hours, and if not sent during normal business hours, then
on the recipient’s next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one business day after the business day of deposit with a nationally
recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on
Schedule A hereto, with copies to such counsel set forth next to a party’s name on Schedule A hereto (which shall not constitute notice), or to the principal office of the Company and to the attention of the Chief
Executive Officer, in the case of the Company, or to such email address or address as subsequently modified by written notice given in accordance with this Section 6.5; provided, however, that any notice sent to Venrock must be sent via email
or with a copy via email. If notice is given to the Company, it shall be sent to the address as set forth on the Company’s signature page to this Agreement. If notice is given to the Investors, a copy (which shall not constitute notice) shall
also be given to Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, CA 94304, Attention: Steve Bochner, SBochner@wsgr.com. 

(b) Consent to Electronic Notice. Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General
Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address set forth below such
Investor’s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company. Each Investor agrees to promptly notify the Company of any change in such stockholder’s electronic mail
address, and that failure to do so shall not affect the foregoing. 

  
 21. 

 6.6 Amendments and Waivers. Any term of this Agreement may be amended, modified or
terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the
Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment
allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.
Notwithstanding the foregoing, (a) this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such
amendment, modification, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the
same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction) and (b) an amendment, modification, termination to or
waiver of Sections 3.1 and 3.2, Section 4 and any other section of this Agreement applicable to the Major Investors (including this clause (b) of this Section 6.6) shall require only the written consent of the Company and the holders
of a majority of the Registrable Securities then outstanding and held by the Major Investors. Notwithstanding the foregoing, the definition of “Major Investor” in Section 1.19 may not be amended, and the observance thereof may not be
waived (either generally or in a particulate instance and either retroactively or prospectively), such that a Major Investor no longer constitutes a “Major Investor” hereunder without the prior written consent of such Major Investor.
Notwithstanding the foregoing, Schedule A hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and
Schedule A hereto may also be amended by the Company after the date of this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a party to this Agreement in accordance with
Section 6.9. The Company shall give prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or waiver. Any
amendment, modification, termination, or waiver effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition,
or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Stock. All shares of Registrable Securities held
or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliates may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the
Series B Preferred Stock after the date hereof, any purchaser of such shares of Series B Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter
shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to
be bound by all of the obligations as an “Investor” hereunder. 

  
 22. 

 6.10 Entire Agreement. This Agreement (including Schedule A hereto) constitutes the
full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 

6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of
the State of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any
suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of the State of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and agree not to
assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or
execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY
COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY
DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY
KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.12 Delays or Omissions. No
delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or
nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any
other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.13 Amendment and Restatement of Prior Agreement. The Prior Agreement is hereby amended and restated and superseded in its
entirety and restated herein. Such amendment and restatement shall be effective upon the execution of this Agreement by the Company and the parties required for an amendment pursuant to Section 6.6 of the Prior Agreement. Upon such execution,
all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released and superseded in their entirety by the provisions hereof and shall have no further force or effect, including, without limitation, all rights to
future stock issuances and any notice period associated therewith otherwise applicable to the transactions contemplated by the Purchase Agreement. 

[Remainder of Page Intentionally Left Blank] 

  
 23. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	COMPANY: 
	
	ARTIVA BIOTHERAPEUTICS, INC. 
		
	By:	 	 /s/ Fred Aslan, M.D.

		 	Name:   Fred Aslan, M.D.
		 	Title:     Chief Executive Officer
			
		 	Address:	 	 4747 Executive Drive
 Suite 1150

San Diego, CA 92121

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Venrock Healthcare Capital Partners EG, L.P.
	By: VHCP Management EG, LLC
	Its: General Partner
		
	By:	 	 /s/ Nimish Shah

		 	Name:	 	Nimish Shah
		 	Title:	 	Authorized Signatory

  

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Logos Opportunities Fund II, L.P.
	By: Logos Opportunities GP, LLC
	Its General Partner
		
	By:	 	 /s/ Graham Walmsley

		 	Name:	 	Graham Walmsley
		 	Title:	 	Managing Member
		
	By:	 	 /s/ Arsani William

		 	Name:	 	Arsani William
		 	Title:	 	Managing Partner

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Capital Research and Management Company, for and on behalf of SMALLCAP World Fund, Inc.
		
	By:	 	 /s/ Walter R. Burkley

		 	Name:	 	Walter R. Burkley
		 	Title:	 	Authorized Signatory

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
	 By: Wellington Management Company LLP,

as investment advisor

		
	By:	 	 /s/ Peter N. McIsaac

		 	Name:	 	Peter N. McIsaac
		 	Title:	 	Managing Director and Counsel

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Cormorant Private Equity Fund III, LP
	By: Cormorant Private Healthcare GP III, LLC
		
	By:	 	 /s/ Bihua Chen

		 	Name:	 	Bihua Chen
		 	Title:	 	Managing Member

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Cormorant Global Healthcare Master Fund, LP
	By: Cormorant Global Healthcare GP, LLC
		
	By:	 	 /s/ Bihua Chen

		 	Name:	 	Bihua Chen
		 	Title:	 	Managing Member

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	CRMA SPV, L.P.
	By: Cormorant Asset Management, LP, Its attorney-in-fact
		
	By:	 	 /s/ Bihua Chen

		 	Name:	 	Bihua Chen
		 	Title:	 	Managing Member

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund
	By: Franklin Advisers, Inc., as investment manager
		
	By:	 	 /s/ Evan McCulloch

		 	Name:	 	Evan McCulloch
		 	Title:	 	Vice President

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Franklin Strategic Series – Franklin Biotechnology Discovery Fund
	By: Franklin Advisers, Inc., as investment manager
		
	By:	 	 /s/ Evan McCulloch

		 	Name:	 	Evan McCulloch
		 	Title:	 	Vice President

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Janus Henderson Biotech Innovation Master Fund Limited
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

		 	Name:	 	Andrew Acker
		 	Title:	 	Authorized Signatory

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Janus Henderson Capital Funds plc on behalf of its series Janus Henderson Global Life Sciences Fund
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

		 	Name:	 	Andrew Acker
		 	Title:	 	Authorized Signatory

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Janus Henderson Horizon Fund – Biotechnology Fund
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

		 	Name:	 	Andrew Acker
		 	Title:	 	Authorized Signatory

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	RTW Master Fund, Ltd.
		
	By:	 	 /s/ Roderick Wong, M.D.

		 	Name:	 	Roderick Wong, M.D.
		 	Title:	 	Director

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	RTW Innovation Master Fund, Ltd.
		
	By:	 	 /s/ Roderick Wong, M.D.

		 	Name:	 	Roderick Wong, M.D.
		 	Title:	 	Director

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	RTW Venture Fund Limited
	By: RTW Investments, LP, its Investment Manager
		
	By:	 	 /s/ Roderick Wong, M.D.

		 	Name:	 	Roderick Wong, M.D.
		 	Title:	 	Managing Partner

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	CITADEL MULTI-STRATEGY EQUITIES MASTER FUND LTD.
	By: Citadel Advisors LLC, its portfolio manager
		
	By:	 	 /s/ Christopher L. Ramsay

		 	Name:	 	Christopher L. Ramsay
		 	Title:	 	Authorized Signatory

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Acuta Capital Fund, LP
	By: Acuta Capital Partners, LLC
	Its: General Partner
		
	By:	 	 /s/ Scott R. Smith

		 	Name:	 	Scott R. Smith
		 	Title:	 	Chief Operating Officer

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Acuta Opportunity Fund, LP
	By: Acuta Capital Partners, LLC
	Its: General Partner
		
	By:	 	 /s/ Scott R. Smith

		 	Name:	 	Scott R. Smith
		 	Title:	 	Chief Operating Officer

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	EcoR1 Capital Fund, L.P.
	By: EcoR1 Capital, LLC, its General Partner
		
	By:	 	 /s/ Oleg Nodelman

		 	Name:	 	Oleg Nodelman
		 	Title:	 	Manager

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	EcoR1 Capital Fund Qualified, L.P.
	By: EcoR1 Capital, LLC, its General Partner
		
	By:	 	 /s/ Oleg Nodelman

		 	Name:	 	Oleg Nodelman
		 	Title:	 	Manager

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	EcoR1 Venture Opportunity Fund, L.P.
	By: Biotech Opportunity GP, LLC, its General Partner
		
	By:	 	 /s/ Oleg Nodelman

		 	Name:	 	Oleg Nodelman
		 	Title:	 	Manager

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Green Cross Holdings Corporation
		
	By:	 	 /s/ Yong-Jun Huh

		 	Name:	 	Yong-Jun Huh
		 	Title:	 	Chief Executive Officer

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Green Cross LabCell Corporation
		
	By:	 	 /s/ Dae-Woo Park

		 	Name:	 	Dae-Woo Park
		 	Title:	 	Chief Executive Officer

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	5AM Ventures VI, L.P.
	By: 5AM Partners VI, LLC, its General Partner
		
	By:	 	 /s/ Andrew Schwab

		 	Name:	 	Andrew Schwab
		 	Title:	 	Managing Partner

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	 venBio Global Strategic Fund III, L.P.

By: venBio Global Strategic GP III, L.P., its general partner
By: venBio Global Strategic GP III, Ltd., its general partner

		
	By:	 	 /s/ Aaron Royston

		 	Name:	 	Aaron Royston
		 	Title:	 	Director

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	 RA Capital Healthcare Fund, L.P.

By: RA Capital Healthcare Fund GP, LLC, its General Partner

		
	By:	 	 /s/ Rajeev Shah

		 	Name:	 	Rajeev Shah
		 	Title:	 	Manager

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Blackwell Partners LLC – Series A
		
	By:	 	 /s/ Rajeev Shah

		 	Name:	 	Rajeev Shah
		 	Title:	 	Authorized Signatory

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	 RA Capital Nexus Fund, L.P.

By: RA Capital Nexus Fund GP, LLC, its General Partner

		
	By:	 	 /s/ Rajeev Shah

		 	Name:	 	Rajeev Shah
		 	Title:	 	Manager

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	Medivate-DAvalue Fund No.03
	
	By: Medivate Partners, LLC
		
	By:	 	 /s/ S. Roger Kang

		 	Name:	 	S. Roger Kang
		 	Title:	 	Managing Partner
	
	By: DA Value Investment Co., Ltd.
		
	By:	 	 /s/ Jin Oh Park

		 	Name:	 	Jin Oh Park
		 	Title:	 	Deputy CEO

  

 SCHEDULE A 

INVESTORS 
  

					
	 Name
	  	 Address
	  	 Email

			
	Venrock Healthcare Capital Partners EG, L.P.	  	 7 Bryant Park, 23rd Floor
 New York, NY
10018
 Attn: Nimish Shah
	  	
			
	Logos Opportunities Fund II, L.P.	  	 1 Letterman Drive
 Building D, Suite D3-700
 San Francisco, CA 94129
	  	
			
	SMALLCAP World Fund, Inc.	  	 333 S. Hope Street, 55th floor

Los Angeles, California 90071
 c/o Capital Research and Management
Company
 Attn:
	  	
			
	Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	  	 c/o Wellington Management Company LLP
 Legal and
Compliance
 280 Congress Street
 Boston, MA 02210

Attn:
 With a copy (which shall not constitute notice) to:

Wilmer Cutler Pickering Hale and Dorr LLP
 60 State Street

Boston, MA 02109
 Attn:
	  	
			
	Cormorant Private Equity Fund III, LP	  	 c/o Cormorant Asset Management LP
 200 Clarendon
Street 52nd Floor
 Boston, MA 02116
 Attn:

Telephone:
	  	

					
	 Name
	  	 Address
	  	 Email

			
	Cormorant Global Healthcare Master Fund, LP	  	 c/o Cormorant Asset Management LP
 200 Clarendon
Street 52nd Floor
 Boston, MA 02116
 Attn:

Telephone:
	  	
			
	CRMA SPV, L.P.	  	 c/o Cormorant Asset Management LP
 200 Clarendon
Street 52nd Floor
 Boston, MA 02116
 Attn:

Telephone:
	  	
			
	Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund	  	 c/o Franklin Advisers, Inc.
 One Franklin
Parkway
 San Mateo, CA 94403
 Attn:
	  	
			
	Franklin Strategic Series – Franklin Biotechnology Discovery Fund	  	 c/o Franklin Advisers, Inc.
 One Franklin
Parkway
 San Mateo, CA 94403
 Attn:
	  	
			
	Janus Henderson Biotech Innovation Master Fund Limited	  	 c/o Janus Capital Management LLC
 151 Detroit
Street
 Denver, CO 80206
 Attn:
	  	
			
	Janus Henderson Capital Funds plc on behalf of its series Janus Henderson Global Life Sciences Fund	  	 c/o Janus Capital Management LLC
 151 Detroit
Street
 Denver, CO 80206
 Attn:
	  	
			
	Janus Henderson Horizon Fund—Biotechnology Fund	  	 c/o Janus Capital Management LLC
 151 Detroit
Street
 Denver, CO 80206
 Attn:
	  	

					
	 Name
	  	 Address
	  	 Email

			
	RTW Master Fund, Ltd.	  	 c/o RTW Investments, LP
 40 10th Avenue, Floor
7
 New York, NY 10014
 Attention:
	  	
			
	RTW Innovation Master Fund, Ltd.	  	 c/o RTW Investments, LP
 40 10th Avenue, Floor
7
 New York, NY 10014
 Attention:
	  	
			
	RTW Venture Fund Limited	  	 c/o RTW Investments, LP
 40 10th Avenue, Floor
7
 New York, NY 10014
 Attention:
	  	
			
	Citadel Multi-Strategy Equities Master Fund Ltd.	  	 c/o Citadel Advisors LLC
 601 Lexington
Avenue
 New York, New York 10022
 Attention:

With copies to:
  

Choate, Hall & Stewart, LLP
 Two International Place

Boston, MA 02100
 Attention:
	  	
			
	 Acuta Capital Fund, LP
 Attention: Scott Smith,
Chief Operating Officer
	  	 1301 Shoreway Road, Suite 350
 Belmont, CA
94002
 (650) 486-0581
	  	
			
	 Acuta Opportunity Fund, LP
 Attention: Scott
Smith, Chief Operating Officer
	  	 1301 Shoreway Road, Suite 350
 Belmont, CA
94002
 (650) 486-0581
	  	
			
	EcoR1 Capital Fund, L.P.	  	 c/o EcoR1 Capital, LLC
 357 Tehama Street #3

San Francisco, CA 94103
 Attention:

Telephone:
	  	
			
	EcoR1 Capital Fund Qualified, L.P.	  	 c/o EcoR1 Capital, LLC
 357 Tehama Street #3

San Francisco, CA 94103
 Attention:

Telephone:
	  	

					
	 Name
	  	 Address
	  	 Email

			
	EcoR1 Venture Opportunity Fund, L.P.	  	 c/o EcoR1 Capital, LLC
 357 Tehama Street #3

San Francisco, CA 94103
 Attention:

Telephone:
	  	
			
	5AM Ventures VI, L.P.	  	 501 Second Street, Ste. 350
 San Francisco, CA
94107
	  	
			
	Green Cross Holdings Corporation	  	107 Ihyeon-ro, 30beon-gil,
Giheung-gu, Yongin-si,
Gyeonggi-do, 16924 Republic of Korea	  	
			
	Green Cross LabCell Corporation	  	107 Ihyeon-ro, 30beon-gil,
Giheung-gu, Yongin-si,
Gyeonggi-do, 16924 Republic of Korea	  	
			
	venBio Global Strategic Fund III, L.P	  	 venBio Partners LLC
 1700 Owens Street, Suite
595
 San Francisco, CA 94158
 Attention:
	  	
			
	RA Capital Healthcare Fund, L.P.	  	 RA Capital Management, L.P.
 200 Berkeley
Street, 18th Floor
 Boston, MA 02116

Attention:
	  	
			
	Blackwell Partners LLC – Series A	  	 280 S. Mangum Street, Suite 210
 Durham, NC
27701
 Attention:
	  	
			
	RA Capital Nexus Fund, L.P.	  	 RA Capital Management, L.P.
 200 Berkeley
Street, 18th Floor
 Boston, MA 02116

Attention:
	  	
			
	Medivate-DAvalue Fund No.03	  	 15F, Kwangil Plaza,
 331, Gangnam-dero, Seocho-gu,
 Seoul, Korea 06627

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]